BioWorld

July 24, 2006

View Archived Issues

Solid Earnings For Amgen As Aranesp Hits $1B For Quarter

Amgen Inc. soundly beat estimates for the second quarter, led by a boost in product revenue, including a 26 percent increase in sales of the anemia drug Aranesp. (BioWorld Today) Read More

ViroPharma's Generic Fight Takes On FDA Rule Change

Read More

Survey Points To PDUFA As Reason For Low FDA Morale

Read More

Cleveland BioLabs: $10.2M For Radioprotectant Drugs

Read More

Other News To Note

Read More

Appointments And Advancements

Read More